Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxylanthanum Carbonate · 1 trial · 1 indication
Tolerability of clinically effective doses of OLC as assessed by the incidence of treatment-related AEs leading to study drug discontinuation during the Maintenance Period.
| Arm | Type | Description |
|---|---|---|
| All Patients | EXPERIMENTAL | All patients with chronic kidney disease with hyperphosphatemia |
| Name | Type | Description |
|---|---|---|
| Oxylanthanum Carbonate | DRUG | Phosphate Binder to Reduce Hyperphosphatemia |
Inclusion Criteria: 1. Patient must be ≥18 years of age. 2. Patient must be willing and capable of giving written Informed Consent, adhering to dosing and visit schedules, and meeting all study requirements. 3. Patient must be willing and able to swallow whole tablets. 4. Patient has chronic kidney...
Oxylanthanum Carbonate is an investigational small molecule being developed for patients with Chronic Kidney Disease Requiring Chronic Dialysis. It is intended for use in the nephrology therapeutic area. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Oxylanthanum Carbonate is being developed by Unicycive Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol UNCY. The company is conducting clinical research to evaluate the drug's tolerability in patients with chronic kidney disease who require dialysis.
Oxylanthanum Carbonate is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied for safety and tolerability. The drug is being evaluated in patients with Chronic Kidney Disease Requiring Chronic Dialysis.
Oxylanthanum Carbonate has one completed clinical trial, identified as NCT06218290, titled "A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis." This Phase 2 study enrolled 106 participants in the United States and was an uncontrolled, open-label trial.
Oxylanthanum Carbonate is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed trial, NCT06218290, assessed tolerability in 106 patients with chronic kidney disease on dialysis, but the drug has not yet received marketing authorization from regulatory agencies.